Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.88
CUR's Cash to Debt is ranked lower than
72% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. CUR: 1.88 )
Ranked among companies with meaningful Cash to Debt only.
CUR' s Cash to Debt Range Over the Past 10 Years
Min: 1.09  Med: N/A Max: No Debt
Current: 1.88
Equity to Asset 0.06
CUR's Equity to Asset is ranked lower than
90% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CUR: 0.06 )
Ranked among companies with meaningful Equity to Asset only.
CUR' s Equity to Asset Range Over the Past 10 Years
Min: -0.81  Med: 0.63 Max: 0.93
Current: 0.06
-0.81
0.93
F-Score: 2
Z-Score: -22.18
M-Score: -4.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -163475.00
CUR's Operating margin (%) is ranked lower than
99% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. CUR: -163475.00 )
Ranked among companies with meaningful Operating margin (%) only.
CUR' s Operating margin (%) Range Over the Past 10 Years
Min: -163475  Med: -2285.14 Max: -507.12
Current: -163475
-163475
-507.12
Net-margin (%) -173850.00
CUR's Net-margin (%) is ranked lower than
99% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. CUR: -173850.00 )
Ranked among companies with meaningful Net-margin (%) only.
CUR' s Net-margin (%) Range Over the Past 10 Years
Min: -173850  Med: -2494.67 Max: -534.63
Current: -173850
-173850
-534.63
ROE (%) -358.75
CUR's ROE (%) is ranked lower than
96% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. CUR: -358.75 )
Ranked among companies with meaningful ROE (%) only.
CUR' s ROE (%) Range Over the Past 10 Years
Min: -1295.32  Med: -246.11 Max: -147.69
Current: -358.75
-1295.32
-147.69
ROA (%) -121.21
CUR's ROA (%) is ranked lower than
90% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. CUR: -121.21 )
Ranked among companies with meaningful ROA (%) only.
CUR' s ROA (%) Range Over the Past 10 Years
Min: -481.63  Med: -174.29 Max: -91.88
Current: -121.21
-481.63
-91.88
ROC (Joel Greenblatt) (%) -5588.85
CUR's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. CUR: -5588.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CUR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -10200  Med: -7570.82 Max: -3482.22
Current: -5588.85
-10200
-3482.22
Revenue Growth (3Y)(%) -100.00
CUR's Revenue Growth (3Y)(%) is ranked lower than
99% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CUR: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CUR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100 Max: 15.6
Current: -100
0
15.6
EBITDA Growth (3Y)(%) -3.70
CUR's EBITDA Growth (3Y)(%) is ranked lower than
54% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. CUR: -3.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CUR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.5  Med: -6.85 Max: 36.2
Current: -3.7
-17.5
36.2
» CUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

CUR Guru Trades in

CUR Guru Trades in

Q2 2015

CUR Guru Trades in Q2 2015

George Soros 18,000 sh (New)
» More
Q3 2015

CUR Guru Trades in Q3 2015

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CERU, AMEX:CANF, NAS:CLBS, NAS:ONCS, NAS:HTBX, NAS:ICCC, OTCPK:CLCS, NAS:OPXA, OTCPK:PTGEF, NAS:MRNS, NAS:CLSN, OTCPK:QBIO, OTCPK:LVCLF, OTCPK:PMCB, NAS:APTO, OTCPK:MNTM, OTCPK:SPRWF, NAS:PULM, NAS:SBOT, NAS:CERC » details
Traded in other countries:7NS.Germany,
Neuralstem Inc is a biotechnology company. It is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs.

Neuralstem Inc was incorporated in 1996 in the state of Maryland. In 2001 it re-incorporated in the state of Delaware. It is engaged in development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. The Company has developed and also maintains a portfolio of patents and patent applications that form the proprietary base of its research and development efforts in the area of neural stem cell research, and related technologies. Its technology base, in combination with its know-how, and collaborative projects with research institutions, provide a competitive advantage and would facilitate the successful development and commercialization of products for use in treatment of an array of neurodegenerative conditions and in regenerative repair of acute disease. The Company is focused on leveraging its key assets, including its intellectual property, its scientific team, its facilities and its capital, to accelerate the advancement of its stem cell technologies. In addition, it is pursuing strategic collaborations with members of academia. The Company manufactures its cells both in-house and on an outsource basis. It uses these cells in its research and collaborative programs. It outsources all the manufacturing and storage of its stem cells to be used in pre-clinical works, and which are accordingly subject to higher FDA requirements, to Charles River Laboratories, Inc., of Wilmington, Massachusetts. The Company's competitors include multinational pharmaceutical companies, specialty biotechnology companies and chemical and medical products companies operating in the fields of regenerative medicine, cell therapy, tissue engineering and tissue regeneration. Many of these companies are well-established and possess technical, research and development, financial and sales and marketing resources greater than the Company. The Company is subject to U.S. federal, state, local and international laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its business.

Ratios

vs
industry
vs
history
P/B 35.71
CUR's P/B is ranked lower than
96% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. CUR: 35.71 )
Ranked among companies with meaningful P/B only.
CUR' s P/B Range Over the Past 10 Years
Min: 1.85  Med: 12.75 Max: 59.26
Current: 35.71
1.85
59.26
Current Ratio 1.37
CUR's Current Ratio is ranked lower than
84% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. CUR: 1.37 )
Ranked among companies with meaningful Current Ratio only.
CUR' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 3.98 Max: 16.97
Current: 1.37
0.52
16.97
Quick Ratio 1.37
CUR's Quick Ratio is ranked lower than
79% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CUR: 1.37 )
Ranked among companies with meaningful Quick Ratio only.
CUR' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 3.98 Max: 16.97
Current: 1.37
0.52
16.97
Days Sales Outstanding 152.08
CUR's Days Sales Outstanding is ranked lower than
85% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. CUR: 152.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
CUR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.68  Med: 125.81 Max: 4341.58
Current: 152.08
2.68
4341.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -21.70
CUR's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CUR: -21.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CUR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24  Med: -15.4 Max: -7
Current: -21.7
-24
-7

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -79.70
CUR's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CUR: -79.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CUR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -116.3  Med: 0 Max: 0
Current: -79.7
-116.3
0

More Statistics

Revenue (TTM) (Mil) $0.01
EPS (TTM) $ -0.22
Beta1.28
Short Percentage of Float4.92%
52-Week Range $0.19 - 1.96
Shares Outstanding (Mil)114.76

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 0 0 0
EPS ($) -0.20 -0.21 -0.22
EPS w/o NRI ($) -0.20 -0.21 -0.22
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CUR

Headlines

Articles On GuruFocus.com
Neuralstem Inc. Reports Operating Results (10-Q) Nov 15 2010 
Neuralstem Inc. Reports Operating Results (10-Q) Aug 16 2010 
Neuralstem Inc. Reports Operating Results (10-Q) May 17 2010 
Weekly CFO Buys Highlight: Neuralstem Inc., Converted Organics Inc., Princeton National Bancorp Inc. Jan 09 2010 
Weekly CEO Buy Highlights: Helix Energy Solutions Group Inc, Neuralstem Inc, Saul Centers Inc, Casua Jan 09 2010 
Weekly CFO Buy Highlights: Neuralstem Inc., New Generation Biofuels Holdings, Converted Organics, Or Jan 04 2010 
Neuralstem Inc. Reports Operating Results (10-Q) Nov 16 2009 
Neuralstem Inc. Reports Operating Results (10-Q) Aug 14 2009 

More From Other Websites
NEURALSTEM, INC. Financials Aug 19 2016
ETF’s with exposure to Neuralstem, Inc. : August 19, 2016 Aug 19 2016
Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 Aug 18 2016
curasan accelerates sales growth in the first six months due to rising foreign demand Aug 18 2016
Neuralstem reports 2Q loss Aug 11 2016
Neuralstem reports 2Q loss Aug 11 2016
Neuralstem Reports Second Quarter 2016 Results and Provides Business and Clinical Updates Aug 11 2016
NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 11 2016
Neuralstem Reports Second Quarter 2016 Results and Provides Business and Clinical Updates Aug 11 2016
NEURALSTEM, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Aug 09 2016
ETF’s with exposure to Neuralstem, Inc. : July 21, 2016 Jul 21 2016
Stocks Coverage on the Healthcare Sector for Biostar Pharma, GlobeImmune, Neuralstem, and GW Pharma Jul 18 2016
NEURALSTEM, INC. Files SEC form 8-K, Other Events Jun 23 2016
Annual general shareholders ’ meeting of curasan AG fully supports plans of the management board Jun 23 2016
NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 21 2016
Neuralstem Announces NSI-189 Shows Enhancement of Long-Term Potentiation In Vitro Jun 21 2016
Neuralstem Announces NSI-189 Shows Enhancement of Long-Term Potentiation In Vitro Jun 21 2016
NEURALSTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 20 2016
NEURALSTEM, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors... Jun 16 2016
NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)